| Sanara MedTech Inc. and InfuSystem Holdings, Inc. Announce Exclusive United States Distribution Agreement with, and Minority Investment in, ChemoMouthpiece, LLC |
Globe Newswire |
09/11 |
06:30 |
| The Atrisco Solar & Storage Project Has Commenced Commercial Operations |
Globe Newswire |
09/11 |
06:01 |
| Celiac Disease Diagnostics Market to Reach US$ 1.42 Billion by 2034, Driven by 8.5% CAGR | Fact.MR Report |
Globe Newswire |
09/11 |
06:00 |
| Big Data Analytics Market to Reach $1.1 Trillion, Globally, by 2032 at 14.5% CAGR: Allied Market Research |
Globe Newswire |
09/11 |
05:38 |
| IGI Announces Publication in Nature Cancer on ISB 2001, IGI's Innovative Trispecific Antibody for Relapsed/Refractory Multiple Myeloma |
Globe Newswire |
09/11 |
05:00 |
| SOLASTA Bio Completes $14m Series A to Accelerate Nature-Inspired Crop Protection |
Globe Newswire |
09/11 |
04:51 |
| Oxford-Harrington Rare Disease Centre Appoints Influential UK Leader in Health Innovation Policy, Baroness Nicola Blackwood, to its Advisory Council |
Globe Newswire |
09/11 |
04:00 |
| OKX Ventures Partner Jeff Ren Moderates Panel on APAC's Investment Potential at Aptos Experience |
Globe Newswire |
09/11 |
04:00 |
| LinkGevity Secures Place in Prestigious SPACE-H Accelerator Program |
Globe Newswire |
09/11 |
04:00 |
| Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU |
Globe Newswire |
09/11 |
01:05 |
| Dupixent® (dupilumab) Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria (CSU) |
Globe Newswire |
09/11 |
01:04 |
| Bioversys Announces Strategic Investment From GIBF2 and Launch of BV100 Clinical Program in China |
Globe Newswire |
09/11 |
01:00 |
| Press Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study |
Globe Newswire |
09/11 |
01:00 |
| James Earl Jones’ Darth Vader voice lives on through AI. Voice actors see promise and peril in that |
AP Online |
09/11 |
00:59 |
| Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial |
Globe Newswire |
09/11 |
00:59 |
| OKX Ventures Invests in Nytro Lab's Castile; Beta Test for AAA Web 3 RPG Launched on September 10 |
Globe Newswire |
09/10 |
23:15 |
| OKX is TOKEN2049 Singapore Title Sponsor for Third Straight Year |
Globe Newswire |
09/10 |
23:00 |
| Francine becomes a hurricane as Louisiana residents brace for expected Wednesday landfall |
AP Online |
09/10 |
22:55 |
| DXC TECHNOLOGY SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against DXC Technology Company - DXC |
Globe Newswire |
09/10 |
22:48 |
| CAE SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against CAE, Inc. - CAE |
Globe Newswire |
09/10 |
22:44 |
| SEVB Showcases Energy Storage Cells & Solutions at RE+ 2024 from 9-12 Sept. in L.A. |
Globe Newswire |
09/10 |
21:09 |
| Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Lifecore, Spire Global, Oddity Tech, and Arbor Realty and Encourages Investors to Contact the Firm |
Globe Newswire |
09/10 |
21:00 |
| Fast Debt Recovery Specialist Among First Licensed Under Singapore's New Debt Collection Rules |
Globe Newswire |
09/10 |
20:52 |
| Hydraulic Fluids Market 2023 to 2033: Steady Growth Forecasted with Key Players and Opportunities | Future Market Insights, Inc. |
Globe Newswire |
09/10 |
20:30 |
| Cuomo defends COVID-19 nursing home decisions in combative House committee hearing |
AP Online |
09/10 |
19:58 |
